The 2016 revision to the World Health Organization classification of myeloid neoplasms includes two distinct CEBPA-related disease entities: AML with biallelic CEBPA mutations (CEBPABI) and AML with germline CEBPA mutations. Here, CEBPA is linked to myeloid neoplasm.